Drugs Made In America Acquisition II Ordinary Shares's EBIT is $-1.4M, below the sector sector average of $2.3T.
Get informed when a big investor buys or sells
+ FollowAs of Sep 30, 2026
Trailing 12 months ending Sep 30, 2026
Drugs Made In America Acquisition II Ordinary Shares (DMII) currently reports a EBIT of $-1.4M as of September 2026. That compares with $-290K in the prior-year period — down 364.7% year over year. That is below the sector sector average of $2.3T. Use the charts on this page to explore Drugs Made In America Acquisition II Ordinary Shares's EBIT history and peer comparisons.
Drugs Made In America Acquisition II Ordinary Shares's EBIT decreased from $-290K to $-1.4M — a 364.7% year-over-year decrease (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Drugs Made In America Acquisition II Ordinary Shares's EBIT of $-1.4M is lower than the its sector sector average of $2.3T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
Drugs Made In America Acquisition II Ordinary Shares reported $-1.4M in EBIT as of September 2026. That compares with $-290K in the prior-year period — down 364.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current EBIT of $-1.4M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $2.3T. From there, open related valuation or income-statement pages for Drugs Made In America Acquisition II Ordinary Shares, and consider following DMII for alerts when major investors trade the stock.